High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma

Tumor-specific mutations can result in immunogenic neoantigens, both of which have been correlated with responsiveness to immune checkpoint inhibitors in highly mutagenic cancers. However, early results of single-agent checkpoint inhibitors in multiple myeloma (MM) have been underwhelming. Therefore...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood Cancer J
Päätekijät: Miller, A, Asmann, Y, Cattaneo, L, Braggio, E, Keats, J, Auclair, D, Lonial, S, Russell, S J, Stewart, A K
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group 2017
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5709757/
https://ncbi.nlm.nih.gov/pubmed/28937974
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2017.94
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia